VTRS

Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio.

A comparison of two Medical Services sector stocks, Viatris (VTRS) and Avantor (AVTR), both holding a Zacks Rank #2 (Buy) rating. Based on valuation metrics including forward P/E ratio (7.01 vs 19.51), PEG ratio (1.92 vs 11.93), and P/B ratio (1.44 vs 1.9), Viatris emerges as the superior value opportunity with a Value grade of A compared to Avantor's C grade.

Viatris (VTRS) is presented as an attractive value investment opportunity, holding a Zacks Rank #2 (Buy) rating with an 'A' Value grade. The stock demonstrates undervaluation across multiple metrics including a P/B ratio of 0.75 (below industry average of 2.17), P/S ratio of 1.37 (below industry average of 1.54), and P/CF ratio of 5.21 (significantly below industry average of 11.92), suggesting solid cash flow and earnings outlook.

Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, more than double the S&P 500. The article highlights Viatris (VTRS) as a stock to watch with a #3 Hold rank and VGM Score of A, noting recent upward earnings estimate revisions and positive momentum.

Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. Market attention is now focused on the upcoming Friday employment report. Viatris (VTRS) is highlighted as a stock to watch with a Hold rating and attractive valuation metrics.

Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% (RYZUMVI®) for treating presbyopia in adults, expanding its previous indication for pharmacologically-induced mydriasis. The approval was supported by positive Phase 3 VEGA-2 and VEGA-3 trial results and will trigger a milestone payment from commercial partner Viatris Inc. Presbyopia affects approximately 90% of U.S. adults over 45, and the drug offers a non-invasive treatment option.

Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business.

The WisdomTree U.S. MidCap Dividend ETF (DON) is a smart beta ETF offering exposure to mid-cap dividend-paying stocks with a 0.38% expense ratio and 2.41% dividend yield. With $3.77 billion in assets and 295 holdings, it has delivered 6.93% returns year-to-date with medium risk (beta 0.86). However, cheaper alternatives like Vanguard's VOE (0.05% expense ratio) and iShares' IWS (0.23% expense ratio) offer lower-cost options for similar market exposure.